Stockscreener 앱 받기
8.12
3.79%
-0.32
시간 외 거래:
8.49
0.37
+4.56%
전일 마감가:
$8.44
열려 있는:
$8.29
하루 거래량:
56,238
Relative Volume:
0.99
시가총액:
$25.81M
수익:
-
순이익/손실:
$-68.80M
주가수익비율:
-6.9402
EPS:
-1.17
순현금흐름:
$-59.06M
1주 성능:
-6.24%
1개월 성능:
-10.87%
6개월 성능:
+13.09%
1년 성능:
+1,627%
1일 변동 폭
$7.70
$8.61
1주일 범위
$7.70
$9.12
52주 변동 폭
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.12 | 26.83M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-10 | 재개 | Chardan Capital Markets | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Buyout Rumor: Should I invest in Passage Bio Inc before earningsInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Coverage Initiated by Analysts at Chardan Capital - Defense World
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67 - Defense World
Retail Surge: What is the dividend yield of Passage Bio Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Ideas: Can Passage Bio Inc. reach all time highs this yearQuarterly Portfolio Summary & Long-Term Growth Plans - mfd.ru
Gm1 Gangliosidosis Treatment Market Witness Booming Growth: - openPR.com
Earnings Miss: Is PAYC stock a buy or sellTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Gap Down: How does Passage Bio Inc perform in inflationary periodsWeekly Stock Summary & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Analyst Calls: Is Information Services Group Inc likely to announce a buyback2025 Risk Factors & High Conviction Buy Zone Picks - baoquankhu1.vn
Market Rankings: Why is Royce Small Cap Trust Inc stock going downProduct Launch & Low Drawdown Investment Ideas - baoquankhu1.vn
Insider Trends: Is TETRA Technologies Inc. a cyclical or defensive stockMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Death Cross: Why is Peloton Interactive Inc stock going up2025 Fundamental Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Is Cardlytics Inc. stock overvalued by current metrics2025 Risk Factors & Accurate Technical Buy Alerts - bollywoodhelpline.com
Aug Volume: Is RYAAY stock forming a cup and handleAnalyst Downgrade & Risk Managed Investment Strategies - baoquankhu1.vn
US Market Wrap: How do insiders feel about VSCOJuly 2025 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Is Passage Bio Incs ROIC above industry averageEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Sentiment Watch: Does Passage Bio Inc have pricing powerJuly 2025 Snapshot & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Institution Moves: Will NVEC stock reach all time highs in 20252025 Growth vs Value & Daily Market Momentum Tracking - Bộ Nội Vụ
Insider Selling: Passage Bio (NASDAQ:PASG) CEO Sells $75,161.44 in Stock - MarketBeat
Passage Bio, Inc. (NASDAQ:PASG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Does Passage Bio Inc. stock trade at a discount to peers2025 Macro Impact & Real-Time Chart Breakout Alerts - Улправда
Why BTSG stock is rated strong buyMarket Volume Summary & Consistent Profit Focused Trading Strategies - Улправда
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):